Patent ID: 7691568

Claim:
A method for treating a disease in a human who is in need of treatment with an anti-CD20 antibody, wherein a CD20 antigen is expressed in a target cell relating to the disease, wherein the CD-20 antigen is expressed at a level of 1×10 3 to 1×10 5 molecules per cell, said method comprising administering to said human an anti-CD20 antibody composition, wherein said anti-CD20 antibody composition comprises anti-CD20 antibody molecules, wherein said anti-CD20 antibody molecules are produced by a CHO cell, wherein said anti-CD20 antibody molecules comprise a Fc region comprising complex N-glycoside-linked sugar chains bound to the Fc region though N-acetylglucosamine of the reducing terminal of the sugar chains, and wherein 100% of said anti-CD20 antibody molecules do not contain sugar chains with a fucose bound to the N-acetylglucosamine, wherein said CHO cell has no α1,6-fucosyltransferase activity as a result of a genetic engineering method, and wherein said CHO cell is resistant to a lectin recognizing a sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through α-bond in a complex N-glycoside-linked sugar chain.